Radius Recycling, Inc. (RDUS)
(Delayed Data from NSDQ)
$18.48 USD
-0.06 (-0.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $18.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.48 USD
-0.06 (-0.32%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $18.48 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Earnings Preview: Radius Recycling (RDUS) Q3 Earnings Expected to Decline
by Zacks Equity Research
Radius Recycling (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concrete Pumping (BBCP) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Concrete Pumping (BBCP) delivered earnings and revenue surprises of -28.57% and 3.55%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
GFL Environmental (GFL) Soars 10.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
GFL Environmental (GFL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Analysts Estimate Radius Recycling (RDUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Radius Recycling (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Core & Main (CNM) Q4 Earnings Match Estimates
by Zacks Equity Research
Core & Main (CNM) delivered earnings and revenue surprises of 0% and 0.41%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
Quest Resource (QRHC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Quest Resource (QRHC) delivered earnings and revenue surprises of -120% and 6.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
ArcelorMittal (MT) Surges 5.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
ArcelorMittal (MT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Fusion Pharmaceuticals Inc. (FUSN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fusion Pharmaceuticals Inc. (FUSN) delivered earnings and revenue surprises of 16.98% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Radius (RDUS) Randomizes Patient in Prader-Willi Syndrome Study
by Zacks Equity Research
Radius (RDUS) randomizes the first patient in the SCOUT-015 study of pipeline candidate, RAD011, for Prader-Willi Syndrome.
Radius (RDUS) to Go Private With $890M Deal, Shares Gain
by Zacks Equity Research
Radius (RDUS) will go private following the acquisition by Gurnet Point Capital and Patient Square Capital.
Radius (RDUS), Menarini Submit NDA for Breast Cancer Drug
by Zacks Equity Research
Radius (RDUS) and partner The Menarini Group submit a new drug application to the FDA for elacestrant for treating patients with ER+/HER2- advanced or metastatic breast cancer.
Radius (RDUS) to Stop Work on Abaloparatide Transdermal System
by Zacks Equity Research
Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.
Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug
by Zacks Equity Research
Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.
Do Options Traders Know Something About Radius Health (RDUS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Radius Health (RDUS) stock based on the movements in the options market lately.
Radius (RDUS) Q1 Loss Wider Than Expected, Revenues Decline
by Zacks Equity Research
Radius (RDUS) posts a y/y wider Q1 loss and misses revenue estimates.
Radius Health (RDUS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of -85.71% and 16.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Radius Health (RDUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Radius Health (RDUS) Could Surge 91%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 90.9% upside potential for Radius Health (RDUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.
Radius Health (RDUS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Radius Health (RDUS) delivered earnings and revenue surprises of 5.71% and 3.30%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 157.45% and 42.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Radius Health (RDUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Radius Health (RDUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for January 26th
by Zacks Equity Research
ISRG, KOP, LPL, NOA, and RDUS have been added to the Zacks Rank #5 (Strong Sell) List on January 26, 2021.
Are Options Traders Betting on a Big Move in Radius Health (RDUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Radius Health (RDUS) stock based on the movements in the options market lately.
Radius (RDUS) Announces Data on Breast Cancer Drug, Abalo-TDS
by Zacks Equity Research
Radius Health (RDUS) provides detailed results on breast cancer drug and from the phase III wearABLe study.